Repositioning Candidate Details
| Candidate ID: | R0492 |
| Source ID: | DB01327 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cefazolin |
| Synonyms: | (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefamezin; Cefazolin; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; CEZ |
| Molecular Formula: | C14H14N8O4S3 |
| SMILES: | [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O |
| Structure: |
|
| DrugBank Description: | A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. |
| CAS Number: | 25953-19-9 |
| Molecular Weight: | 454.507 |
| DrugBank Indication: | Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis. |
| DrugBank Pharmacology: | Cefazolin (also known as cefazoline or cephazolin) is a semi-synthetic first generation cephalosporin for parenteral administration. Cefazolin has broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. |
| DrugBank MoA: | In vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. |
| Targets: | Penicillin-binding protein 1A inhibitor; Penicillin-binding protein 1B inhibitor; Penicillin-binding protein 1C inhibitor; Penicillin-binding protein 2 inhibitor; Peptidoglycan synthase FtsI inhibitor; Serum paraoxonase/arylesterase 1 inhibitor; Interleukin-15 inhibitor; Interleukin-2 inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|